16th Annual Scientific Meeting Posters

Poster pdfs and abstracts are in alphabetical order by first author.

Hemodynamic latency is associated with reduced intelligence across the lifespan: an fMRI Dynamic Causal Model study of aging cerebrovascular integrity and cognitive ability (Abstract)

Anderson

Towards more efficient Clinical Outcome Assessment selection methods to accelerate drug development in epilepsy (Abstract)

Bishop

Modelling of peripheral nerve pain and osteoarthritis placebo response working towards a unique model of the placebo response in chronic pain (Abstract)

Branders

Evaluation of therapeutic expectation therapeutic misconception and suggestibility initial validation of Placebo Response Mitigation Scales PReMIS (Abstract)

Capodilupo

Sensitivity analysis of lumateperone efficacy in schizophrenia impact of imbalance in dropouts and assumptions for patient dropouts (Abstract)

Chen

A – Measuring negative symptoms using computerized vocal analysis requires machine learning and large feature sets (Abstract)

Cohen

E – Managing the placebo and nocebo perils applying the placebo-control reminder script in psychosis trials (Abstract)

Cohen

The relationship of the Personal and Social Performance Scale PSP with the NSA-16 PANSS and the CGI (Abstract)

Daniel

Reducing the variance of sleep-related endpoints through repeated in-home measurements (Abstract)

Dorffner

Scrutinizing social interaction as a functional status drug development tool for use in pre-dementia (Abstract)

Fieo

Psychometric evaluation of the Suicide Ideation and Behavior Assessment Tool SIBAT using data from two phase 3 studies (Abstract)

Fu

Use of digital biomarkers in a Parkinsons Disease open-label extension study for frequent and objective assessment of treatment response (Abstract)

Galatzer-Levy

Data-driven versus knowledge-driven predictive analytics application to N-of-1 pharmacodynamic interactions in CNS trials (Abstract)

Geerts

Using artificial intelligence machine learning to empirically measure intentional dose non-adherence impact on trial methodology and interpretation (Abstract)

Getz

VRFCAT data supporting FDA COA Qualification Program application (Abstract)

Horan

Sifting through the smoke using human laboratory models to unpack cannabis effects on psychiatric symptoms in adults with OCD (Abstract)

Kayser

Relationship of clinical insight with psychopathology social cognition impulsivity and neurocognition in schizophrenia (Abstract)

Khan

eCOA coupled with audio video recordings reduces PANSS identical ratings in schizophrenia data (Abstract)

Kott

Peer-review process in linguistic validation to improve translation of COA instruments in international trials (Abstract)

Krishna

Assessing the meaningful change threshold of Quality of Life in Depression Scale QLDS using data from two phase 3 studies (Abstract)

Li

Methods for evaluating temporal and directional relationships between sleep quality and symptom severity in bipolar disorder trial (Abstract)

Lipschitz

Qualitative study to establish content validity of the ABC-CFXS for treatment efficacy in Fragile X Syndrome (Abstract)

Merikle

Exploring MMSE scoring and administration errors in dementia clinical trials (Abstract)

Miller

Distinct altered neurochemistry in the hippocampus of individuals with bipolar disorder and comorbid anxiety evidence from 1H MRS (Abstract)

Paim Diaz

Novel digital outcomes in multiple sclerosis trials use of wearable biosensors to collect real-world activity data in elezanumab studies (Abstract)

Pfleeger

Joint modeling of multiple longitudinal suicidality indices to understand treatment effect (Abstract)

Qiu

In-vivo alpha-7 nicotinic acetylcholine receptor availability and relationship to cognition in schizophrenia (Abstract)

Radhakrishnan

Tracking changes in cognition in MCI and Alzheimers Disease over 6 months using a speech-based digital biomarker (Abstract)

Robin

Determining meaningful change in hopelessness assessed with the Beck Hopelessness Scale in MDD patients with active suicidal ideation (Abstract)

Rozjabek

Assessing treatment adherence in bipolar disorder does increasing sources of information improve correlation with symptoms (Abstract)

Sajatovic

Assessing the impact of travel time and distance on participation in clinical research (Abstract)

Sauder

Development of a Composite Site Performance Score optimizing site selection and trial methodology (Abstract)

Shafner

Duplicate subjects in Alzheimers disease unintended consequence of longer studies (Abstract)

Shiovitz

Up-front matching for prospective observational studies to mimic randomization (Abstract)

Turkoz

Preliminary baseline data on the Multiple Sclerosis Individualized Outcome Assessment MSIOA in a phase 2 trial (Abstract)

Villalta-Gil

Prediction of medication adherence in clinical trials using machine learning (Abstract)

Zhang